WO1981003546A1 - Method and apparatus for determining glucose in biological fluids - Google Patents

Method and apparatus for determining glucose in biological fluids Download PDF

Info

Publication number
WO1981003546A1
WO1981003546A1 PCT/US1981/000725 US8100725W WO8103546A1 WO 1981003546 A1 WO1981003546 A1 WO 1981003546A1 US 8100725 W US8100725 W US 8100725W WO 8103546 A1 WO8103546 A1 WO 8103546A1
Authority
WO
WIPO (PCT)
Prior art keywords
voltage
sweep
limit
glucose
volts
Prior art date
Application number
PCT/US1981/000725
Other languages
French (fr)
Inventor
J Giner
H Lerner
J Soeldner
Original Assignee
Joslin Diabetes Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc filed Critical Joslin Diabetes Center Inc
Priority to DE813152065T priority Critical patent/DE3152065A1/en
Priority to BR8108636A priority patent/BR8108636A/en
Priority to GB08404395A priority patent/GB2140567B/en
Priority to NL8120252A priority patent/NL8120252A/nl
Publication of WO1981003546A1 publication Critical patent/WO1981003546A1/en
Priority to NO82820274A priority patent/NO159421C/en
Priority to DK42982A priority patent/DK42982A/en
Priority to FI820328A priority patent/FI68323C/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/30Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
    • G01N27/3271Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3274Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration

Definitions

  • This invention relates to sensing the concentration of glucose in biological fluids. • It is desirable to monitor accurately glucose concentration in biological fluids, particularly us-ing a device that is implantable in living organisms; for example, such a device would be useful for diabetics in timing the administration of insulin and food. Glucose concentration in simple solutions--e.g. ,
  • Krebs-Ringer buffer can be monitored electrochemically by measuring the current density at a platinum electrode while varying the electrode potential relative to a standard.
  • current generated by electrochemical reactions is responsive to the glucose concentration. Accordingly, current measured while varying the electrode potential over a range, first from negative to positive (anodic) and then back again (cathodic) , will be a function of glucose concentration.* Interference with glucose measurement due to the presence of other biological substances—particularly amino acids and urea--is a serious problem. Such substances undergo electrochemical reactions during the voltage sweep, generating currents independent of glucose concentration and , reducing sensitivity to glucose.
  • Marinic et al. infra, indicates that there is considerable sensitivity of current density to glucose concentration in the presence of urea with cathodic potential sweeps at potentials below about - 100 mV; that article concludes, however, for anodic potential sweeps,
  • an accurate measure of glucose concentration is obtained in biological fluids.
  • the portion of integration is selected so that the charge responsive to glucose concentration has predominantly the same algebraic sign throughout the portion, and so that the charge responsive to interfering components of the fluid (or to any specific interfering component) has a positive sign in one segment of the portion and a negative sign in another segment, so that the glucose-responsive charge, and thus sensitivity to glucose, is reinforced throughout the portion of integration, and the charge responsive to interfering substances at least partially cancels, thus reducing interference from those components or changes in concentration of those components.
  • Total charge is normalized in the form of the ratio of total algebraic charge to total absolute value of charge; the lower limit of the voltage sweep is between -1.0 and -0.6 volts and the upper limit is between 0.7 and 1.1 volts; the voltag .
  • e sweep includes dwell periods at the limits, and the rates of voltage change during the anodic and cathodic sweeps are constant; integration takes place continuously during one complete voltage sweep (or, alternatively, substantially including the anodic sweep between -0.45 volts and the upper limit, the dwell at the upper limit, and the entire cathodic sweep) ; the rate of voltage change during cathodic voltage sweep may be more rapid than during the anodic voltage sweep; and the voltage sweep may include holding periods between the limits at potentials at which glucose undergoes an electrochemical reaction.
  • glucose concentration in biological fluids can be determined by measuring the current at the electrode at a point in a specific region between 0.2 volts and 0.6 volts during the anodic voltage variation selected to be sensitive to changes in levels of glucose concentration but relatively insensitive to levels of other constituents of the fluid.
  • Fig. 1 is a block diagram of the circuitry for an implantable glucose sensor embodying one aspect of the invention.
  • Fig. 2 is a block diagram of the circuitry for an implantable glucose sensor embodying another aspect of the invention.
  • Figs. 3a and 3b show, diagramatically, the elements of an electrode cell used with the embodiments of Figs. 1 or 2.
  • Figs. 4a, b, c, d, e and f are graphs related to - 4 -
  • Figs. 5a, b, and c are graphs related to the embodiment of Fig. 2. Integration of Current 5 Fig. 1 shows in block form, one embodiment of implantable circuitry including glucose sensing cell 40.
  • Figs. 3a and 3b show potentiostat 30 connected to control the potential drop between glucose oxidation electrode 50 and reference electrode 52.
  • potentiostat 30 0 compares and equates that voltage (V meas.) to the voltage (V appl.) generated by function generator 20 by allowing current to flow in a measurement circuit formed by leads 51, glucose electrode 50, the biological medium, counter electrode 54, lead 53 and potentiostat 30.
  • Reference 5 electrode 52 is connected to the function generator by lead 55.
  • signal processor 60 is connected to the measurement circuit and integrates current in the circuit in response to timed signals from function 0 generator 20.
  • Modulator/transmitter 70 is connected to signal processor 60 and transmits an FM signal corresponding to the output of processor 60 in response to a transmit signal from function generator , 20.
  • Sensor cell
  • FIG. 3 has a glucose oxidation electrode 50 separated 5 by barrier 56 (which is an ion exchange membrane treated to allow passage of cations only) from counter electrode 54.
  • barrier 56 which is an ion exchange membrane treated to allow passage of cations only
  • a glucose-permeable membrane 58 separates electrode 50 from high molecular weight compounds in the biological medium, and a biocompatible hydrophobic membrane 59 at the 0 counter electrode allows reaction products (gasses) to diffuse to surrounding tissue, while electrically insulating the electrode from that tissue.
  • Reference electrode 52 is a silver/silver chloride electrode.
  • Counter electrode 54 is a carbon electrode.
  • Glucose electrode 50 is a teflon-bonded platinized platinum electrode prepared as follows: An electrode sheet is formed from a suspension of Teflon-30 (Dupont) and platinum black (Engelhard) , respectively. This suspension is then filtered through a membrane to give a uniform layer of the Teflon and platinum on the membrane. This layered structure is then placed atop a platinum mesh screen with the Teflon-platinum layer mixture contacting the platinum screen. The resultant layered structure is subjected to pressure and then sintered to obtain, the final electrode structure. The electrode is cut from the sheet.
  • function generator 20 In operation, function generator 20 generates a waveform which varies back and forth between two limits.
  • Line 2 in Fig. 4a shows a typical trapezoidal waveform in which voltage is maintained at -0.8V for 60 sec, then increased at a rate of 2 volts/min. to +0.8V. This region of increasing voltage is called the anodic voltage sweep. After a 30 second dwell at 0.8V, voltage is decreased, again at 2 volts/min. to the lower limit of -0.8V. The region of ' decreasing voltage is the cathodic voltage sweep.
  • Electrode 50 As the voltage is applied to the electrode, electrochemical reaction of glucose is catalyzed at electrode 50. Glucose from the surrounding tissue permeates the membrane, and reaction products are transported away from the electrode. Barrier 56 insulates the two electrodes, but allows transfer of cations to the counter electrode to complete the current measurement circuit.
  • the biological medium produces currents at specific portions of the voltage sweep.
  • glucose oxidation occurs at specific portions of the sweep; in those portions, the current generated (which will include current generated as a result of reaction of - 6 -
  • background constituents as well as glucose-responsive current can be used to indicate glucose concentration.
  • the current related to a particular interfering substance is positive in one segment of the portion and negative in another segment, while the effect of glucose-related currents is essentially positive throughout the portion.
  • signal processor 60 integrates current and provides a measurement of total algebraic charge Q. over the region of integration; alternatively the signal processor can provide a signal representing ratio of the total algebraic charge to the absolute value of total charge Q./
  • the graphs of Fig. 4 represent examples of operations conducted under simulated physiologic conditions. They are perfomed at 37°C under an atmosphere of 95% nitrogen, 5% CO-.
  • Amino acids are provided in a stock solution of 23 different amino acids at concentrations proportional to physiological concentrations. Urea is present in the physiological concentrations indicated.
  • the potentiostat used (Princeton Applied Research Corp., Model PAR-173) has automatic IR compensation.
  • the programmable function generator is Model 73211 from Data Trak, Research, Inc.
  • the glucose electrode has a geometric area of 0.19 cm , 2 a Pt coat of 25 mg per cm and a real area (from coulomet ⁇ c hydrogen stripping measurement) of 485 cm 2..
  • the reference electrode is a standard saturated colomel (Hg, Hg 2 Cl 2 , KC1) electrode, and the glucose permeable membrane is Nucleopore, 500 Angstrom.
  • Fig. 4b shows current measured in the system before (line 1) and after (line 2) the addition of glucose.
  • the difference attributable to glucose (line.3) results in a charge (shaded) which is essentially positive over the entire waveform.
  • the background charge (from the background solution and from the amino acids and urea) essentially cancels, while the glucose-responsive charge is essentially positive and, sensitivity to glucose " is ' increased by integration.
  • changes in charges associated with changes in urea and amino acid concentrations, respectively essentially cancel, thus enhancing sensitivity to glucose.
  • Fig. 2 shows a diagram of apparatus similar to Fig. 1, except that function generator 20 signals current measurement by current measurement means 80, and transmission of a signal representing that measurement by transmitter 70.
  • Figs. 5a, b and c represent the results of current measurement, under conditions described for the current integration examples above.
  • the region between 0.2 and 0.6 volts of the anodic portion of the sweep shows a clear response to changes in glucose concentration, and a lack of response to changes in concentrations of amino acids and urea. Measurement at a point within that region (e.g., 0.3 volts) thus provides a measurement of glucose concentrations notwithstanding the presence of urea and amino acids.
  • Fig. 1 and of Fig. 2 would include a receiver (not shown) outside of the organism in which the sensor is implanted, to receive the signal transmitted by the sensor and translate that signal into data representing glucose concentration. Alternatively the receiver could trigger an alarm when glucose concentration varies outside predetermined limits.
  • the voltage waveform may be varied in several ways: the dwell times can be changed but should preferably be at least 2 seconds; the lower limit can be increased to, e.g., -1.0 volts, but excessive generation of hydrogen results from a limit significantly below that level.
  • the upper limit can vary, e.g., from 0.7 to 1.1 volts; a voltage significantly above 1.1V causes corrosion of the electrode.
  • Holding periods may be introduced during the anodic and/or the cathodic portion of the sweep, preferably at potentials at which glucose reactions occur so as to increase the amount of time spent at such potentials and enhance sensitivity and selectivity to glucose; the rate of voltage change in the anodic and cathodic sweeps may be different—e.g. , the anodic sweep may be relative slower to increase the amount of time spent at voltages which produce currents sensitive and selective for glucose.
  • the voltage variation could include discontinuities such as jumps from a limit to- the measuring voltage.
  • the claims include glucose sensors that are not implanted--e.g. , clinical laboratory sensors.
  • the biological fluids can include any fluids taken from living organisms or fluids simulating conditions in a living organism including, without limitation, blood, urine, buffer solutions, and saline solutions.

Abstract

Prior art electroanalytical methods are subject to interferences by other species found in biological fluids. This invention overcomes this problem by the provision of an apparatus in which the voltage between the electrodes (50, 54) is varied in a sweep ranging from a first limit to a second limit and back toward the first limit, and the current is integrated with respect to time during at least a portion of the voltage variation selected to produce a total charge specifically sensitive to glucose concentration and relatively insensitive to other components in the fluid; alternatively the current is measured at a point in a specific region of the voltage variation.

Description

METHODANDAPPARATUSFORDETERMININGGLUCOSEIN BIOLOGICALFLUIDS
Background of the Invention This invention relates to sensing the concentration of glucose in biological fluids. It is desirable to monitor accurately glucose concentration in biological fluids, particularly us-ing a device that is implantable in living organisms; for example, such a device would be useful for diabetics in timing the administration of insulin and food. Glucose concentration in simple solutions--e.g. ,
Krebs-Ringer buffer—can be monitored electrochemically by measuring the current density at a platinum electrode while varying the electrode potential relative to a standard. At various electrode potentials, current generated by electrochemical reactions is responsive to the glucose concentration. Accordingly, current measured while varying the electrode potential over a range, first from negative to positive (anodic) and then back again (cathodic) , will be a function of glucose concentration.* Interference with glucose measurement due to the presence of other biological substances—particularly amino acids and urea--is a serious problem. Such substances undergo electrochemical reactions during the voltage sweep, generating currents independent of glucose concentration and, reducing sensitivity to glucose.
Marinic et al. , infra, indicates that there is considerable sensitivity of current density to glucose concentration in the presence of urea with cathodic potential sweeps at potentials below about - 100 mV; that article concludes, however, for anodic potential sweeps,
*Marincic et al., "Electrochemical Glucose Oxidation on a Platinized Platinum Electrode in Krebs-Ringer Solution, I. Potentiodynamic Studies", 126 J, Electrochem. Soc. 43, Jan. 1979 and "III. Effect of urea", 126 J. Electrochem. Soc. Oct. 1979. that inhibition by urea precludes glucose concentration measurement.
Gebhart el al., "Development of an Implantable Electrocatalytic Glucose Sensor", 5 Bioelectrochemistry and Bioenergetics 607 (1978) indicates (Fig. 9) a correlation between glucose concentration in the presence of amino acids and charge produced at the"electrode at a specific voltage; between periods of integration, voltage is shifted to a rejuvenation potential.
Summary of the Invention
According to one aspect of the invention, by applying a voltage to the electrode, varying the voltage in a sweep from a first limit to a second limit and back toward the first limit, and integrating the current at the electrode over at least a portion of the voltage sweep selected to produce a total charge sensitive to glucose concentration and to be relatively insensitive to other components in the biological fluid, an accurate measure of glucose concentration is obtained in biological fluids.
In preferred embodiments, the portion of integration is selected so that the charge responsive to glucose concentration has predominantly the same algebraic sign throughout the portion, and so that the charge responsive to interfering components of the fluid (or to any specific interfering component) has a positive sign in one segment of the portion and a negative sign in another segment, so that the glucose-responsive charge, and thus sensitivity to glucose, is reinforced throughout the portion of integration, and the charge responsive to interfering substances at least partially cancels, thus reducing interference from those components or changes in concentration of those components. Total charge is normalized in the form of the ratio of total algebraic charge to total absolute value of charge; the lower limit of the voltage sweep is between -1.0 and -0.6 volts and the upper limit is between 0.7 and 1.1 volts; the voltag.e sweep includes dwell periods at the limits, and the rates of voltage change during the anodic and cathodic sweeps are constant; integration takes place continuously during one complete voltage sweep (or, alternatively, substantially including the anodic sweep between -0.45 volts and the upper limit, the dwell at the upper limit, and the entire cathodic sweep) ; the rate of voltage change during cathodic voltage sweep may be more rapid than during the anodic voltage sweep; and the voltage sweep may include holding periods between the limits at potentials at which glucose undergoes an electrochemical reaction.
According to another aspect of the invention, glucose concentration in biological fluids can be determined by measuring the current at the electrode at a point in a specific region between 0.2 volts and 0.6 volts during the anodic voltage variation selected to be sensitive to changes in levels of glucose concentration but relatively insensitive to levels of other constituents of the fluid.
Description of the Preferred Embodiments We turn now to a description of the preferred embodiments of the invention, first briefly describing the drawings thereof. Drawings
Fig. 1 is a block diagram of the circuitry for an implantable glucose sensor embodying one aspect of the invention.
Fig. 2 is a block diagram of the circuitry for an implantable glucose sensor embodying another aspect of the invention.
Figs. 3a and 3b show, diagramatically, the elements of an electrode cell used with the embodiments of Figs. 1 or 2.
Figs. 4a, b, c, d, e and f are graphs related to - 4 -
the embodiment of Fig. 1.
Figs. 5a, b, and c are graphs related to the embodiment of Fig. 2. Integration of Current 5 Fig. 1 shows in block form, one embodiment of implantable circuitry including glucose sensing cell 40. Figs. 3a and 3b show potentiostat 30 connected to control the potential drop between glucose oxidation electrode 50 and reference electrode 52. Specifically, potentiostat 30 0 compares and equates that voltage (V meas.) to the voltage (V appl.) generated by function generator 20 by allowing current to flow in a measurement circuit formed by leads 51, glucose electrode 50, the biological medium, counter electrode 54, lead 53 and potentiostat 30. Reference 5 electrode 52 is connected to the function generator by lead 55.
In Fig. 1, signal processor 60 is connected to the measurement circuit and integrates current in the circuit in response to timed signals from function 0 generator 20. Modulator/transmitter 70 is connected to signal processor 60 and transmits an FM signal corresponding to the output of processor 60 in response to a transmit signal from function generator, 20. Sensor cell
*-
40 (Fig. 3) has a glucose oxidation electrode 50 separated 5 by barrier 56 (which is an ion exchange membrane treated to allow passage of cations only) from counter electrode 54. A glucose-permeable membrane 58 separates electrode 50 from high molecular weight compounds in the biological medium, and a biocompatible hydrophobic membrane 59 at the 0 counter electrode allows reaction products (gasses) to diffuse to surrounding tissue, while electrically insulating the electrode from that tissue. Reference electrode 52 is a silver/silver chloride electrode. Counter electrode 54 is a carbon electrode. 5 Glucose electrode 50 is a teflon-bonded platinized platinum electrode prepared as follows: An electrode sheet is formed from a suspension of Teflon-30 (Dupont) and platinum black (Engelhard) , respectively. This suspension is then filtered through a membrane to give a uniform layer of the Teflon and platinum on the membrane. This layered structure is then placed atop a platinum mesh screen with the Teflon-platinum layer mixture contacting the platinum screen. The resultant layered structure is subjected to pressure and then sintered to obtain, the final electrode structure. The electrode is cut from the sheet.
In operation, function generator 20 generates a waveform which varies back and forth between two limits. Line 2 in Fig. 4a shows a typical trapezoidal waveform in which voltage is maintained at -0.8V for 60 sec, then increased at a rate of 2 volts/min. to +0.8V. This region of increasing voltage is called the anodic voltage sweep. After a 30 second dwell at 0.8V, voltage is decreased, again at 2 volts/min. to the lower limit of -0.8V. The region of' decreasing voltage is the cathodic voltage sweep. By selecting a voltage sweep which effectively permits glucose oxidation and rejuvenates the catalytic surface of the electrode, continuous sweeps and glucose concentration measurement are possible.
As the voltage is applied to the electrode, electrochemical reaction of glucose is catalyzed at electrode 50. Glucose from the surrounding tissue permeates the membrane, and reaction products are transported away from the electrode. Barrier 56 insulates the two electrodes, but allows transfer of cations to the counter electrode to complete the current measurement circuit.
The biological medium produces currents at specific portions of the voltage sweep. In particular glucose oxidation occurs at specific portions of the sweep; in those portions, the current generated (which will include current generated as a result of reaction of - 6 -
background constituents as well as glucose-responsive current) can be used to indicate glucose concentration. However, electrochemical reactions due to other fluid constituents—specifically urea and amino acids—may affect the current measurement and hinder determination of glucose concentration.
In certain portions of the sweep, the current related to a particular interfering substance is positive in one segment of the portion and negative in another segment, while the effect of glucose-related currents is essentially positive throughout the portion. By integrating cell current over time to obtain total charge at the electrode in that sweep portion, these glucose-reinforcing, interference-cancelling phenomena act to improve greatly the sensitivity to glucose concentration while at the same time reducing the interference experienced. Specifically, signal processor 60 integrates current and provides a measurement of total algebraic charge Q. over the region of integration; alternatively the signal processor can provide a signal representing ratio of the total algebraic charge to the absolute value of total charge Q./|Q. |.
The graphs of Fig. 4 represent examples of operations conducted under simulated physiologic conditions. They are perfomed at 37°C under an atmosphere of 95% nitrogen, 5% CO-. The background fluid is a modified Kreb-Ringer buffer solution (0.109 M NaCl, 0.024 M NaHC03, 0.006 M MgSo4, 0.001 M NaH2P04, pH = 7.4). Amino acids are provided in a stock solution of 23 different amino acids at concentrations proportional to physiological concentrations. Urea is present in the physiological concentrations indicated. The potentiostat used (Princeton Applied Research Corp., Model PAR-173) has automatic IR compensation. The programmable function generator is Model 73211 from Data Trak, Research, Inc.
2 The glucose electrode has a geometric area of 0.19 cm , 2 a Pt coat of 25 mg per cm and a real area (from coulometπc hydrogen stripping measurement) of 485 cm 2..
The reference electrode is a standard saturated colomel (Hg, Hg2Cl2, KC1) electrode, and the glucose permeable membrane is Nucleopore, 500 Angstrom.
When the above-described voltage waveform (line 2 in Fig. 4a) is applied to the Krebs-Ringer buffer alone, the current at the electrode is first negative, then positive and finally negative, as indicated by line 1 in Fig. 4(a). The shaded area under line 1 represents charge, and the positive and negative areas essentially cancel.
Fig. 4b shows current measured in the system before (line 1) and after (line 2) the addition of glucose. The difference attributable to glucose (line.3) results in a charge (shaded) which is essentially positive over the entire waveform.
With the addition of urea (Fig. 4c) or amino acids (Fig. 4d) to the system, the resulting current changes (line 2 in Figs. 4c and d) are positive in some regions of the sweep and negative in other regions, while the current responsive to glucose (line 1) remains essentially positive throughout the sweep.
The following table shows that integrating current over the entire sweep provides an algebraic value of charge (Qt) (or a normalized value of charge in the form of the ratio of algebraic to- total absolute charge (Qt/ Qt ) ) which is sensitive to glucose concentration even in the presence of changing concentrations of amino acids and urea. Figs. 4e and f specifically illustrate the above relationship in the presence of changing concentrations of amino acids. - 8 -
Glucose Electrode Response to Changes in Glucose and Amino Ac id Concentration
Cone . , mg/dl
Amino Qt' Qt
Glucose Acids Urea mCoul |Q t l
.50 35 40 20.0 .087
63 35 40 22.6 .099
75 35 40 24.5 .107
88 35 40 26.0 .114
10 100 35 40 27.6 .122
113 35 40 28.0 ^ .123
125 35 40 30.0 .132
150 35 40 31.9 .141
175 35 40 33.7 .148
15 200 35 40 3.6.3 .160
250 35 40 41.0 .180
50 50 40 23.8 .109
63 50 40 24.3 . .111
75 50 40 24.9 .114
20 88 50 40 27.3 .126
100 50 40 28.8 .133
113 50 40 28.5 .132
125 50 40 28.9 .134
150 50 40 31.2 .144
25 175 50 40 34.4 .159
200 50 40 35.2 .162
250 50 40 38.5 .178 (Chart continued from previous page)
Amino vt '
Glucose Acids Urea mCoul iQ-tI
50 65 40 23.6 .117
63 65 40 23.7 .119
75 65 40 24.4 .123
88 65 40 25.2 .128
100 ' 65 40 26.5 .135
113 65 40 26.7 .137
125 65 40 27.3 .140
150 65 40 29.1 .149
175 65 40 31.3 .160
200 65 40 • 31.9 .165
250 65 40 34.1 .177
Thus, when integrating over the entire voltage sweep, the background charge (from the background solution and from the amino acids and urea) essentially cancels, while the glucose-responsive charge is essentially positive and, sensitivity to glucose" is' increased by integration. Moreover, changes in charges associated with changes in urea and amino acid concentrations, respectively, essentially cancel, thus enhancing sensitivity to glucose.
Referring specifically to Figs. 4c and d, it is apparent that integration need not occur over the entire voltage sweep. Examination of a specific portion of the sweep—substantially including the portion of the anodic sweep from -0.45 volts to 0.8 volts, the dwell at the upper limit, and the entire cathodic sweep—also shows the requisite characte istics for selectivity and sensitivity. Current Measurement
Fig. 2 shows a diagram of apparatus similar to Fig. 1, except that function generator 20 signals current measurement by current measurement means 80, and transmission of a signal representing that measurement by transmitter 70. Figs. 5a, b and c represent the results of current measurement, under conditions described for the current integration examples above. The region between 0.2 and 0.6 volts of the anodic portion of the sweep shows a clear response to changes in glucose concentration, and a lack of response to changes in concentrations of amino acids and urea. Measurement at a point within that region (e.g., 0.3 volts) thus provides a measurement of glucose concentrations notwithstanding the presence of urea and amino acids. For example values of current at 0.3V in the anodic scan for a Krebs-Ringer buffer containing 40 mg/dl of urea and 35 mg/dl of amino acids, taken from a plot such as Fig. 5c, will show a linear relationship between current and glucose concentration. The embodiments of both Fig. 1 and of Fig. 2 would include a receiver (not shown) outside of the organism in which the sensor is implanted, to receive the signal transmitted by the sensor and translate that signal into data representing glucose concentration. Alternatively the receiver could trigger an alarm when glucose concentration varies outside predetermined limits.
Other Embodiments Other embodiments are within the scope of the following claims. By way of example only, the voltage waveform may be varied in several ways: the dwell times can be changed but should preferably be at least 2 seconds; the lower limit can be increased to, e.g., -1.0 volts, but excessive generation of hydrogen results from a limit significantly below that level. The upper limit can vary, e.g., from 0.7 to 1.1 volts; a voltage significantly above 1.1V causes corrosion of the electrode. Holding periods may be introduced during the anodic and/or the cathodic portion of the sweep, preferably at potentials at which glucose reactions occur so as to increase the amount of time spent at such potentials and enhance sensitivity and selectivity to glucose; the rate of voltage change in the anodic and cathodic sweeps may be different—e.g. , the anodic sweep may be relative slower to increase the amount of time spent at voltages which produce currents sensitive and selective for glucose. With respect to the current measurement embodiment of Fig. 2, the voltage variation could include discontinuities such as jumps from a limit to- the measuring voltage.
The claims include glucose sensors that are not implanted--e.g. , clinical laboratory sensors. The biological fluids can include any fluids taken from living organisms or fluids simulating conditions in a living organism including, without limitation, blood, urine, buffer solutions, and saline solutions.

Claims

Claims
1. Apparatus for sensing the concentration of
! glucose in biological fluids comprising
1 . an electrode, 5 a voltage source, means for applying the voltage source to the electrode to cause a current flow therethrough, means for varying said applied voltage in a sweep ranging from a first limit to a second limit and back 10 toward said first limit, and means for integrating current at the electrode with respect to time during at least a portion of said voltage variation selected to produce a total charge sensitive to glucose concentration and relatively 15 insensitive to other components in the fluid.
2. The apparatus of claim 1 in which said portion is selected so that the charge responsive to glucose concentration has predominantly the same algebraic sign throughout said portion, and so that the charge
20 responsive to interfering components of said fluid has a positive sign in one segment of said portion and a negative sign in another segment of said portion, whereby the glucose-responsive charge, and thus sensitivity to glucose, is reinforced, and the charge responsive to
25 interfering substances at least partially cancels, thus reducing such interference.
3. The apparatus of claim 1 or 2 in which the lower limit of' such voltage sweep is between -1.0 and -0.6 volts and the upper limit is between 0.7 and 1.1 volts,
30 said sweep including an anodic sweep from said lower to said upper limit and a cathodic sweep from said upper to said lower limit.
4. The apparatus o.f claim 1 or 2 in which said voltage sweep includes dwell periods at said upper and lower limits, and the rate of voltage change during said anodic and cathodic sweeps is constant.
5. The apparatus of claim 1 or 2 in which said integration takes place continuously during one complete voltage sweep.
6. The apparatus of claim 1 or 2 in which said integration occurs substantially including the anodic sweep between -0.45 volts and said upper limit, the dwell at said upper limit, and the entire cathodic voltage sweep.
7.. The apparatus of claim 1 or 2 in which the rate of voltage change during said cathodic voltage sweep is more rapid than during said anodic voltage sweep.
8. The apparatus of claim 1 or 2 in which said varying of said applied voltage ceases during holding periods between said limits, said holding periods being at potentials at which glucose undergoes an electrochemical reaction.
9. The apparatus of claim 1 o.r 2 in which said portion is selected so that the charge attributable to any specific interfering component of the fluid cancels, whereby changes in concentration of that specific component do not affect the charge measured.
10. The apparatus of claim 1 or 2 in which said apparatus includes means to normalize said total charge in the form of the ratio of the total algebraic charge to the total absolute value of said charge.
11. A. ethod for sensing the concentation of glucose in biological fluids comprising the steps of applying a voltage to an electrode to cause a current flow therethrough, varying said applied voltage in a sweep ranging from a first limit to a second limit and back toward said first limit, and integrating current with respect to time over at least one portion of said voltage variation selected to give a total charge sensitive to glucose concentration and relatively insensitive to other components in the fluid.
12. Apparatus for sensing the concentration of glucose in biological fluids comprising an electrode, a voltage source, means for applying the voltage source to the electrode to cause, a current to flow therethrough, means for varying said applied voltage from a first limit'to a second limit and back toward said first limit, and means for measuring current at the electrode at a point, between 0.2 volts and 0.6 volts during the anodic variation of the voltage sw.eep, selected to be sensitive to changes in levels of glucose concentration in said fluid, but relatively insensitive to levels of other constituents of said fluid.
13. Apparatus of claim 12 in which said lower limit of said voltage variation is between -1.0 and -0.6 volts and the said upper limit is between 0.7 and 1.1 volts.
14. Apparatus of claim 12 in which the rate of change of said voltage variation is constant between said limits, and includes dwell periods at each limit.
15. Apparatus according to claim 14 in which said dwell periods are greater than 2 seconds.
16. Apparatus according to claim 10 wherein said voltage variation includes an anodic sweep and a cathodic sweep, said rate of voltage variation being between 0.5 volts/min. and 4 volts/min.
17. Apparatus according to claim 16 in which the rate of voltage change during said cathodic sweep is more rapid than during said anodic sweep.
18. A method for sensing the concentration of glucose in biological fluids comprising applying a voltage to an electrode to cause a current to flow therethrough, varying said applied voltage in a sweep ranging from a first limit to a second limit and back toward said first limit, and measuring said current at a point in a specific region, between 0.2 volts and 0.6 volts during the anodic variation of said voltage, selected to be sensitive to changes in levels of glucose concentration in said fluid, but relatively insensitive to levels of other constituents of said fluid.
PCT/US1981/000725 1980-06-02 1981-06-01 Method and apparatus for determining glucose in biological fluids WO1981003546A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE813152065T DE3152065A1 (en) 1980-06-02 1981-06-01 METHOD AND APPARATUS FOR DETERMINING GLUCOSE IN BIOLOGICAL FLUIDS
BR8108636A BR8108636A (en) 1980-06-02 1981-06-01 PROCESS AND APPARATUS FOR DETERMINING GLUCOSE IN BIOLOGICAL FLUIDS
GB08404395A GB2140567B (en) 1980-06-02 1981-06-01 Glucose sensor
NL8120252A NL8120252A (en) 1980-06-02 1981-06-01
NO82820274A NO159421C (en) 1980-06-02 1982-01-29 METHOD AND APPARATUS FOR DETERMINING THE GLUCOSE CONTENT IN BIOLOGICAL LIQUIDS.
DK42982A DK42982A (en) 1980-06-02 1982-02-01 DEVICE FOR THE REGISTRATION OF GLUCOSE CONCENTRATION IN BIOLOGICAL FLUID
FI820328A FI68323C (en) 1980-06-02 1982-02-02 GLUKOSGIVARE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/155,198 US4340458A (en) 1980-06-02 1980-06-02 Glucose sensor
US155198 1980-06-02

Publications (1)

Publication Number Publication Date
WO1981003546A1 true WO1981003546A1 (en) 1981-12-10

Family

ID=22554460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1981/000725 WO1981003546A1 (en) 1980-06-02 1981-06-01 Method and apparatus for determining glucose in biological fluids

Country Status (16)

Country Link
US (2) US4340458A (en)
EP (1) EP0052148A4 (en)
JP (1) JPS57500899A (en)
AU (1) AU546417B2 (en)
BR (1) BR8108636A (en)
CA (1) CA1152155A (en)
CH (1) CH660922A5 (en)
DE (1) DE3152065A1 (en)
DK (1) DK42982A (en)
FI (1) FI68323C (en)
GB (2) GB2089048B (en)
MX (1) MX151191A (en)
NL (1) NL8120252A (en)
NO (1) NO159421C (en)
SE (2) SE434887B (en)
WO (1) WO1981003546A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071152A1 (en) * 1981-07-29 1983-02-09 Siemens Aktiengesellschaft Method and apparatus for the determination of urea
EP0245073A2 (en) * 1986-05-06 1987-11-11 The Regents Of The University Of California A complete glucose monitoring system with an implantable, telemetered sensor module
US5645709A (en) * 1993-12-08 1997-07-08 Van Den Bergh Foods Co., Division Of Conopco, Inc. Methods and apparatus for electrochemical measurements
DE102006043718B4 (en) * 2006-09-18 2014-12-31 Alexander Adlassnig Determination of hydrogen peroxide concentrations
EP3096338A1 (en) * 2015-05-21 2016-11-23 Nokia Technologies Oy An apparatus and method for providing a time varying voltage

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407959A (en) * 1980-10-29 1983-10-04 Fuji Electric Co., Ltd. Blood sugar analyzing apparatus
US4440175A (en) * 1981-08-10 1984-04-03 University Patents, Inc. Membrane electrode for non-ionic species
US4729824A (en) * 1982-05-11 1988-03-08 Giner, Inc. Gas sensor and method of using same
DE3228551A1 (en) * 1982-07-30 1984-02-02 Siemens AG, 1000 Berlin und 8000 München METHOD FOR DETERMINING SUGAR CONCENTRATION
DE3228542A1 (en) * 1982-07-30 1984-02-02 Siemens AG, 1000 Berlin und 8000 München METHOD FOR DETERMINING THE CONCENTRATION OF ELECTROCHEMICALLY IMPLEMENTABLE SUBSTANCES
US4826810A (en) * 1983-12-16 1989-05-02 Aoki Thomas T System and method for treating animal body tissues to improve the dietary fuel processing capabilities thereof
US5030333A (en) * 1984-09-13 1991-07-09 Children's Hospital Medical Center Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor
US5047352A (en) * 1985-05-20 1991-09-10 Arch Development Corporation Selective chemical detection by energy modulation of sensors
GB2175399B (en) * 1985-05-20 1989-10-11 Us Energy Selective chemical detection by energy modulation of sensors
US4805624A (en) * 1985-09-09 1989-02-21 The Montefiore Hospital Association Of Western Pa Low-potential electrochemical redox sensors
US4890620A (en) * 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
US5002572A (en) * 1986-09-11 1991-03-26 Picha George J Biological implant with textured surface
US4897162A (en) * 1986-11-14 1990-01-30 The Cleveland Clinic Foundation Pulse voltammetry
US4974929A (en) * 1987-09-22 1990-12-04 Baxter International, Inc. Fiber optical probe connector for physiologic measurement devices
US4953552A (en) * 1989-04-21 1990-09-04 Demarzo Arthur P Blood glucose monitoring system
US5243516A (en) * 1989-12-15 1993-09-07 Boehringer Mannheim Corporation Biosensing instrument and method
TW279133B (en) * 1990-12-13 1996-06-21 Elan Med Tech
US5593852A (en) 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
CA2050057A1 (en) * 1991-03-04 1992-09-05 Adam Heller Interferant eliminating biosensors
US5773270A (en) * 1991-03-12 1998-06-30 Chiron Diagnostics Corporation Three-layered membrane for use in an electrochemical sensor system
US5271736A (en) * 1991-05-13 1993-12-21 Applied Medical Research Collagen disruptive morphology for implants
US5387327A (en) * 1992-10-19 1995-02-07 Duquesne University Of The Holy Ghost Implantable non-enzymatic electrochemical glucose sensor
IE72524B1 (en) * 1994-11-04 1997-04-23 Elan Med Tech Analyte-controlled liquid delivery device and analyte monitor
US5743262A (en) * 1995-06-07 1998-04-28 Masimo Corporation Blood glucose monitoring system
US5711861A (en) * 1995-11-22 1998-01-27 Ward; W. Kenneth Device for monitoring changes in analyte concentration
US5776324A (en) * 1996-05-17 1998-07-07 Encelle, Inc. Electrochemical biosensors
JP3394262B2 (en) 1997-02-06 2003-04-07 セラセンス、インク. Small volume in vitro analyte sensor
US8527026B2 (en) 1997-03-04 2013-09-03 Dexcom, Inc. Device and method for determining analyte levels
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US6862465B2 (en) * 1997-03-04 2005-03-01 Dexcom, Inc. Device and method for determining analyte levels
CA2294610A1 (en) 1997-06-16 1998-12-23 George Moshe Katz Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods
US5922339A (en) * 1998-01-27 1999-07-13 Usala; Anton-Lewis Compositions and methods for biocompatible implants
US6103033A (en) 1998-03-04 2000-08-15 Therasense, Inc. Process for producing an electrochemical biosensor
US6134461A (en) 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6251260B1 (en) 1998-08-24 2001-06-26 Therasense, Inc. Potentiometric sensors for analytic determination
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6654625B1 (en) 1999-06-18 2003-11-25 Therasense, Inc. Mass transport limited in vivo analyte sensor
US6616819B1 (en) 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
WO2003036285A1 (en) * 2001-10-26 2003-05-01 Arkray, Inc. Specific component concentration measuring method and concentration measuring instrument
DE10229542B4 (en) 2002-07-01 2004-05-19 Infineon Technologies Ag Electronic component with multilayer rewiring plate and method for producing the same
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
EP2284266B1 (en) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US8771183B2 (en) 2004-02-17 2014-07-08 Abbott Diabetes Care Inc. Method and system for providing data communication in continuous glucose monitoring and management system
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
AU2004268222B2 (en) 2003-08-21 2010-03-11 Agamatrix, Inc. Method and apparatus for assay of electrochemical properties
USD914881S1 (en) 2003-11-05 2021-03-30 Abbott Diabetes Care Inc. Analyte sensor electronic mount
US20050244811A1 (en) * 2003-12-15 2005-11-03 Nano-Proprietary, Inc. Matrix array nanobiosensor
JP2007523326A (en) 2004-02-06 2007-08-16 バイエル・ヘルスケア・エルエルシー Oxidizable species as internal standards for biosensors and methods of use
EP1751533A2 (en) * 2004-05-14 2007-02-14 Bayer Healthcare, LLC Voltammetric systems for assaying biological analytes
GB2417323A (en) 2004-08-17 2006-02-22 Oxford Biosensors Ltd A method of operating an electrochemical sensor by applying a time variable potential between the electrodes.
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US8545403B2 (en) 2005-12-28 2013-10-01 Abbott Diabetes Care Inc. Medical device insertion
US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US8571624B2 (en) 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US20090105569A1 (en) 2006-04-28 2009-04-23 Abbott Diabetes Care, Inc. Introducer Assembly and Methods of Use
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
ES2717135T3 (en) 2005-07-20 2019-06-19 Ascensia Diabetes Care Holdings Ag Method to signal the user to add an additional sample to a test strip, method to measure the temperature of a sample and methods to determine the concentration of an analyte based on controlled amperometry
US20070117171A1 (en) * 2005-09-13 2007-05-24 Greta Wegner Method of manufacturing a diagnostic test strip
CN101273266B (en) 2005-09-30 2012-08-22 拜尔健康护理有限责任公司 Gated voltammetry
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
EP2083674B1 (en) 2006-10-24 2018-03-07 Ascensia Diabetes Care Holdings AG Transient decay amperometry
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
WO2008150917A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
WO2009076302A1 (en) 2007-12-10 2009-06-18 Bayer Healthcare Llc Control markers for auto-detection of control solution and methods of use
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
US20100213057A1 (en) 2009-02-26 2010-08-26 Benjamin Feldman Self-Powered Analyte Sensor
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
WO2011026147A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte signal processing device and methods
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
EP2549918B2 (en) 2010-03-24 2023-01-25 Abbott Diabetes Care, Inc. Medical device inserters and processes of inserting and using medical devices
US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
AU2012335830B2 (en) 2011-11-07 2017-05-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods
EP4056105B1 (en) 2011-12-11 2023-10-11 Abbott Diabetes Care, Inc. Analyte sensor devices
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
CA2984939A1 (en) 2015-05-14 2016-11-17 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
EP3220137B1 (en) * 2016-03-14 2019-01-23 Roche Diabetes Care GmbH Method for detecting an interferent contribution in a biosensor
CN110461217B (en) 2017-01-23 2022-09-16 雅培糖尿病护理公司 Systems, devices, and methods for analyte sensor insertion
JP7104997B2 (en) * 2018-07-09 2022-07-22 国立研究開発法人物質・材料研究機構 Diagnostic device, analysis method, and program
WO2021158973A1 (en) 2020-02-06 2021-08-12 Trustees Of Boston University Enzyme-based electrochemical nicotine biosensor
WO2021221752A2 (en) 2020-02-06 2021-11-04 Trustees Of Boston University High throughput assay for identifying microbial redox enzymes

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282804A (en) * 1963-04-25 1966-11-01 Robert F Stearn Method and apparatus for analyzing metals, alloys and semiconductors
US3428532A (en) * 1964-02-06 1969-02-18 Continental Oil Co Method for identifying metals and alloys
US3542662A (en) * 1967-04-18 1970-11-24 Du Pont Enzyme electrode
US3623960A (en) * 1970-04-07 1971-11-30 Monsanto Res Corp Glucose determination method
US3837339A (en) * 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US3855101A (en) * 1974-01-24 1974-12-17 Petrolite Corp Dynamic analyzer
US3922205A (en) * 1973-08-20 1975-11-25 Dow Chemical Co Portable polarographic analyzer and quick polarographic determinations
GB1422172A (en) * 1972-01-03 1976-01-21 Siemens Ag Measurement of sugar concentrations
US4132605A (en) * 1976-12-27 1979-01-02 Rockwell International Corporation Method for evaluating the quality of electroplating baths
US4140963A (en) * 1972-01-03 1979-02-20 Siemens Aktiengesellschaft Device for measuring sugar concentration
GB2019580A (en) * 1978-04-20 1979-10-31 Siemens Ag Mehtod of determining sugar content and sensor suitable therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1422172B1 (en) 1961-12-07 1970-11-12 Kopperschmidt & Co Carl W periscope
US3657667A (en) 1969-04-23 1972-04-18 Citizen Watch Co Ltd Oscillator with three-arm mechanical vibrator connected to suppress spurious vibrations
CA977419A (en) * 1971-10-06 1975-11-04 Keith B. Oldham Electroanalysis system employing semi-integration or semi-differentiation

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282804A (en) * 1963-04-25 1966-11-01 Robert F Stearn Method and apparatus for analyzing metals, alloys and semiconductors
US3428532A (en) * 1964-02-06 1969-02-18 Continental Oil Co Method for identifying metals and alloys
US3542662A (en) * 1967-04-18 1970-11-24 Du Pont Enzyme electrode
US3623960A (en) * 1970-04-07 1971-11-30 Monsanto Res Corp Glucose determination method
GB1422172A (en) * 1972-01-03 1976-01-21 Siemens Ag Measurement of sugar concentrations
US4140963A (en) * 1972-01-03 1979-02-20 Siemens Aktiengesellschaft Device for measuring sugar concentration
US3837339A (en) * 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US3922205A (en) * 1973-08-20 1975-11-25 Dow Chemical Co Portable polarographic analyzer and quick polarographic determinations
US3855101A (en) * 1974-01-24 1974-12-17 Petrolite Corp Dynamic analyzer
US4132605A (en) * 1976-12-27 1979-01-02 Rockwell International Corporation Method for evaluating the quality of electroplating baths
US4132605B1 (en) * 1976-12-27 1986-06-10
GB2019580A (en) * 1978-04-20 1979-10-31 Siemens Ag Mehtod of determining sugar content and sensor suitable therefor

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Biochemistry and Bioenergetics, Vol. 5, p. 607, 1978, U. GEBHARDT et al., Development of an Implantable Electrocatalytic Glucose Sensor *
Biomat. Med. Dev. Art. Org., Vol. 6, No. 2, p. 127, 1978, J.R. RAO et al., Electrochemical Behavior of Amino Acids and their Influence on the Anodic Oxidation of Glucose in Neutral Media *
Blood Glucose Monitoring, Georg Thieme publishers, pp. 10-22, 1977, D.A. GOUGH et al. the Status of Electrochemical Sensors for In Vivo Glucose Monitoring *
In Vitro Studies of a Potetially Implantable Electrochemical Glucose Sensor, 1979, J.S. SOELDNER et al. *
J. Electrochemical Soc., Vol. 126, No. 1, p. 43, 1979, LJILJANA MARINCIC et al., Electrochemical Glucose Oxidation of a Platinized Platinum Electrode in Krebs-Ringer Solution *
J. Electrochemical Soc., Vol. 126, No. 10, p. 1687, 1979, LJILJANA MARINCIC et al., Electrochemical Glucose Oxidation on a Platinized Platinum Electrode in Krebs-Ringer Solution *
J. Electrochemical Soc., Vol. 126, No. 2, p. 237, 1979, HARRY LERNER et al., Electrochemical Glucose Oxidation on a Platinized Platinum Electrode in Krebs-Ringer Solution *
The Development of an Implantable Glucose Sensor: Response to Glucose in Bovine Serum Ultrafiltrate, Sept. or Oct. 1980, JOHN R. GUYTON et al. *
Trans. Amer. Soc. Artif. Int. Organs, Vol. 19, p. 352, 1973, KUO WEI CHANG et al., Validation and Bioengeneering Aspects of an Implantable Glucose Sensor *
Transplatation and Clinical Immunology, Vol. 10, p. 165, 1978, CLARK K. COLTON et al., Development of an Implantable Electrochemical Glucose Sensor *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071152A1 (en) * 1981-07-29 1983-02-09 Siemens Aktiengesellschaft Method and apparatus for the determination of urea
EP0245073A2 (en) * 1986-05-06 1987-11-11 The Regents Of The University Of California A complete glucose monitoring system with an implantable, telemetered sensor module
EP0245073A3 (en) * 1986-05-06 1989-03-29 The Regents Of The University Of California A complete glucose monitoring system with an implantable, telemetered sensor module
US5645709A (en) * 1993-12-08 1997-07-08 Van Den Bergh Foods Co., Division Of Conopco, Inc. Methods and apparatus for electrochemical measurements
DE102006043718B4 (en) * 2006-09-18 2014-12-31 Alexander Adlassnig Determination of hydrogen peroxide concentrations
US9938555B2 (en) 2006-09-18 2018-04-10 Alexander Adlassnig Determination of hydrogen peroxide concentrations
EP3096338A1 (en) * 2015-05-21 2016-11-23 Nokia Technologies Oy An apparatus and method for providing a time varying voltage
WO2016185087A1 (en) * 2015-05-21 2016-11-24 Nokia Technologies Oy An apparatus and method for providing a time varying voltage
CN107636784A (en) * 2015-05-21 2018-01-26 诺基亚技术有限公司 The apparatus and method of time variant voltage during offer
CN107636784B (en) * 2015-05-21 2019-05-31 诺基亚技术有限公司 The device and method of time-varying voltage are provided
US11506629B2 (en) 2015-05-21 2022-11-22 Nokia Technologies Oy Apparatus and method for providing a time varying voltage

Also Published As

Publication number Publication date
SE434887B (en) 1984-08-20
BR8108636A (en) 1982-04-13
FI68323C (en) 1985-08-12
SE8200511L (en) 1982-01-29
US4340458A (en) 1982-07-20
FI820328L (en) 1982-02-02
GB2089048A (en) 1982-06-16
GB2140567B (en) 1985-06-05
FI68323B (en) 1985-04-30
CH660922A5 (en) 1987-05-29
US4396464A (en) 1983-08-02
GB2089048B (en) 1985-01-30
NL8120252A (en) 1982-05-03
NO159421C (en) 1988-12-21
DE3152065A1 (en) 1982-08-12
GB8404395D0 (en) 1984-03-28
AU7412681A (en) 1981-12-21
DK42982A (en) 1982-02-01
AU546417B2 (en) 1985-08-29
SE434888B (en) 1984-08-20
NO159421B (en) 1988-09-12
SE8304129D0 (en) 1983-07-25
GB2140567A (en) 1984-11-28
NO820274L (en) 1982-01-29
MX151191A (en) 1984-10-09
SE8304129L (en) 1983-07-25
EP0052148A4 (en) 1983-06-15
EP0052148A1 (en) 1982-05-26
CA1152155A (en) 1983-08-16
JPS57500899A (en) 1982-05-20

Similar Documents

Publication Publication Date Title
AU546417B2 (en) Glucose sensor
EP2416893B1 (en) Microsecond response electrochemical sensors and methods thereof
US7081195B2 (en) Systems and methods for improving electrochemical analyte sensors
US5030333A (en) Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor
US4853091A (en) Method and apparatus for the electrochemical determination of oxygen concentration
US5376244A (en) Electrochemical determination of oxygen concentration
US20070151868A1 (en) Implantable electrode system, method and apparatus for measuring an analyte concentration in a human or animal body
RU2444006C2 (en) Method of determining concentration of hydrogen peroxide and apparatus for realising said method (versions)
KR101294712B1 (en) Method of continuously measuring substrate concentraion
ATE403860T1 (en) DEVICE FOR CONTROLLING THE CHANGE IN CONCENTRATION OF AN ANALYTE
Amatore et al. Effects of restricted diffusion at ultramicroelectrodes in brain tissue: the pool model: theory and experiment for chronoamperometry
CN111683592A (en) Uncorrected in vivo measurement of analytes using electrochemical sensors
DE102011007918A1 (en) biosensor
CN113490454A (en) Apparatus and method for sensor operation for detecting continuous analyte sensing and auto-correction
Preidel et al. A new principle for an electrochemical oxygen sensor
Wang et al. Long voltammetric microelectrode for in vivo monitoring of acetaminophen in primate species
JPH05215712A (en) Electric catalyst glucose sensor
JPS6239388B2 (en)
IE970443A1 (en) Methods of calibrating and testing a sensor for in vivo¹measurement of an analyte and devices for use in such¹methods
Miyasaka et al. Transient measurement of glucose using on-off controllable enzyme electrode with polypyrrole membrane
Lücke et al. The influence of the convulsant pentylenetetrazol on Ca2+-selective microelectrodes (neutral carrier ETH 1001)

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AT AU BR CH DE DK FI GB JP LU NL NO SE

AL Designated countries for regional patents

Designated state(s): AT CH DE FR GB LU NL SE

ENP Entry into the national phase

Ref document number: 1981 9043

Country of ref document: AT

Date of ref document: 19811210

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 820328

Country of ref document: FI

Ref document number: 1981901848

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1981901848

Country of ref document: EP

RET De translation (de og part 6b)

Ref document number: 3152065

Country of ref document: DE

Date of ref document: 19820812

WWE Wipo information: entry into national phase

Ref document number: 3152065

Country of ref document: DE

WWG Wipo information: grant in national office

Ref document number: 820328

Country of ref document: FI

WWW Wipo information: withdrawn in national office

Ref document number: 1981901848

Country of ref document: EP